Glycaemic control efficacy of switching from dipeptidyl peptidase‐4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study ( SWITCH‐SEMA 2 study)
Authors' conclusion
Although the potential for gastrointestinal symptoms should be carefully considered, switching from DPP-4is to oral semaglutide may be beneficial for glycaemic control and metabolic abnormalities in people with higher HbA1c and insulin resistance.
Study context
- Population
- People with T2D receiving DPP-4is17 dropped out
- Participants
- 174 people
- Comparison
- Switch to oral semaglutide vs DPP-4i continuation
- Semaglutiden = 75
- DPP-4in = 82reference
- Primary endpoint
- Change in HbA1c
- Follow-up
- 24 weeks
Methodological detailsmulticentre, open-label, prospective, parallel-group, 17 dropped out
- Multicentre
- Open-label
- Prospective
- Parallel-group
- 17 dropped out
Primary result
As reported in the abstract
week 24
Semaglutide
−0.65
95% CI −0.79–-0.51
DPP-4i
+0.05
95% CI −0.07–0.16
P < 0.001
Secondary outcomes
Body weight, lipid profiles and liver enzymes
- Significantly improved with semaglutide vs DPP-4i continuation
Factors associated with HbA1c improvement after switching to semaglutide
- Baseline HbA1c and HOMA2-R independently associated (multiple linear regression)
Safety
- Discontinuation due to gastrointestinal symptoms — Semaglutide
- 7 events
Original publication
Glycaemic control efficacy of switching from dipeptidyl peptidase‐4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study ( SWITCH‐SEMA 2 study). Diabetes Obes Metab. Published 11 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →